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Abstract: Background: The aim of this study was to assess and compare the performance of
different ultrasound-based International Ovarian Tumor Analysis (IOTA) strategies and subjective
assessment for the diagnosis of early stage ovarian malignancy. Methods: This is a secondary
analysis of a prospective multicenter cross-sectional diagnostic accuracy study that included 1653
patients recruited at 18 centers from 2009 to 2012. All patients underwent standardized transvaginal
ultrasonography by experienced ultrasound investigators. We assessed test performance of the
IOTA Simple Rules (SRs), Simple Rules Risk (SRR), the Assessment of Different NEoplasias in the
adneXa (ADNEX) model and subjective assessment to discriminate between stage I-II ovarian cancer
and benign disease. Reference standard was histology after surgery. Results: 230 (13.9%) patients
proved to have stage I–II primary invasive ovarian malignancy, and 1423 (86.1%) had benign disease.
Sensitivity and specificity with respect to malignancy (95% confidence intervals) of the original SRs
(classifying all inconclusive cases as malignant) were 94.3% (90.6% to 96.7%) and 73.4% (71.0% to
75.6%). Subjective assessment had a sensitivity and specificity of 90.0% (85.4% to 93.2%) and 86.7%
(84.9% to 88.4%), respectively. The areas under the receiver operator characteristic curves of SRR
and ADNEX were 0.917 (0.902 to 0.933) and 0.905 (0.920 to 0.934), respectively. At a 1% risk cut-off,
sensitivity and specificity for SRR were 100% (98.4% to 100%) and 38.0% (35.5% to 40.6%), and for
ADNEX were 100% (98.4% to 100%) and 19.4% (17.4% to 21.5%). At a 30% risk cut-off, sensitivity
and specificity for SRR were 88.3% (83.5% to 91.8%) and 81.1% (79% to 83%), and for ADNEX were
84.5% (80.5% to 89.6%) and 84.5% (82.6% to 86.3%). Conclusion: This study shows that all three IOTA
strategies have good ability to discriminate between stage I-II ovarian malignancy and benign disease.
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1. Introduction
Ovarian tumors are common in women of all ages [1–3]. It has been estimated that in the female
population, the lifetime risk of undergoing surgery for a suspected ovarian neoplasm is 5–10% [4].
However, the incidence of ovarian cancer is low. In Europe, there were 65,538 new cases during 2012,
with an age-adjusted incidence rate of 13.1 per 100,000 women. Still, ovarian cancer is an important
health problem in gynecology, as it is the most lethal gynecological malignancy, with 42,700 deaths
occurring in 2012 in Europe (mortality rate 7.6 per 100,000) [5]. This accounts for 5% of all cancer
deaths in women, which makes ovarian cancer the sixth most lethal cancer in females in Europe [6].
In recent decades, despite advances in cytoreductive radical surgery and cytotoxic chemotherapy,
we have seen only a marginal improvement in the overall survival of patients with ovarian cancer [7].
Almost 60% of patients are diagnosed with advanced disease with regional or distant spread and
an unfavorable long-term prognosis. Five-year relative survival is 46% for all International Federation
of Gynecology and Obstetrics (FIGO) stages [8], but ranges from 90% at Stage I to 4% for Stage IV
disease [6,8]. Therefore, attention for the development of strategies to detect ovarian malignancy at
an early stage using imaging and/or biomarkers is increasing, in order to improve patient survival.
This idea is reflected in the conduction of several large ovarian cancer screening trials [9–11], but also
plays an important role in clinical management of the non-screening population.
Early detection of cancer means that treatment is not delayed and that appropriate staging can be
carried out in specialized surgical centers, which is known to improve survival [12–15].
The best ultrasound method for discrimination between benign and malignant adnexal masses
is the subjective assessment of ultrasound findings by an experienced ultrasound examiner [16–18].
However, as such expert knowledge is not available in each center, the International Ovarian Tumor
Analysis (IOTA) study aims to develop diagnostic algorithms to assist clinicians in characterizing
adnexal pathology, irrespective of their level of expertise. The IOTA group initially published
a consensus paper in order to standardize terms, definitions, and measurements used to assess
ovarian pathology [19]. By prospectively investigating patients presenting with an adnexal mass (i.e.,
non-screening population), this formed the basis for the development of different IOTA methods such
as the Simple Rules (SRs), which are based on five ultrasound features suggestive for a benign lesion
(B-features) and five features suggestive for a malignant lesion (M-features) [20]. The IOTA SRs have
become very popular because they are easy to use, without the need for any calculation. They have
been extensively validated and are incorporated in international guidelines [21,22]. Two systematic
reviews and meta-analyses have concluded that the IOTA SRs are one of the best performing
available diagnostic methods for differentiating between benign and malignant adnexal masses [18,23].
Shortcomings of the SRs are that there are inconclusive results in a proportion of cases (when B and
M features apply or when no features apply) and the absence of an estimated risk of malignancy.
Therefore, the ultrasound features used in the SRs have recently been used to calculate a risk of
malignancy, leading to the Simple Rules Risk (SRR) model [24]. Another logistic regression model
developed by the IOTA group is the Assessment of Different NEoplasias in the adneXa (ADNEX)
model. As a multiclass prediction model, ADNEX not only calculates the likelihood of malignancy
in adnexal masses, but also divides this into the likelihood that the mass is borderline malignant,
stage I primary invasive ovarian cancer, stage II–IV primary invasive ovarian cancer, or a metastasis
in the ovary from another primary tumor [25]. The performance of ADNEX is at least as good as
the performance of previous IOTA methods, as confirmed by external validation studies [26–30].
The ADNEX model is available online and in mobile applications (www.iotagroup.org/adnexmodel/).
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Given the good performance of IOTA strategies in discriminating between benign and malignant
disease in patients presenting with an adnexal mass prior to surgery, we are often confronted with
the question on how IOTA methods could potentially improve detection in ovarian cancer screening.
For the purpose of this special issue of Diagnostics, we assessed and compared the test performance of
various diagnostic IOTA methods and subjective assessment to identify early stage, i.e., FIGO stage I
and II [8], primary invasive ovarian malignancy in a non-screening population.
2. Materials and Methods
2.1. Patients
This study was performed on data of IOTA phase 3 [31], a multicenter cross-sectional diagnostic
accuracy study with prospective data collection. Patients were recruited in 18 centers in six countries
(Sweden, Belgium, Italy, Poland, Spain, and Czech Republic) between October 2009 and May 2012.
The participating centers were either oncology referral centers (i.e., tertiary centers with a specific
gynecological oncology unit) or general hospitals and units with a special interest in gynecological
ultrasound. Ethics approval for IOTA 3 was obtained by the ethics committee of the University
Hospitals Leuven (B32220095331/S51375 approved 21 January 2009) as the main investigating center
as well of the local ethics committees of all contributing centers.
Patients were eligible for IOTA 3 if they presented with at least one adnexal mass (ovarian,
para-ovarian, or tubal), underwent standardized transvaginal ultrasonography by a principal
investigator at one of the participating centers, and were then selected for surgical intervention
by the managing clinician. All examiners were experienced in gynecologic ultrasound. Details on
the ultrasound examination technique and the IOTA terms and definitions used to describe adnexal
pathology have been published elsewhere [19]. More information on data collection can be found in
the original IOTA 3 publication [31]. The pathologist was blinded to the predicted outcomes of the
index tests being compared.
For the purpose this study, only patients having a histopathology diagnosis of a benign mass or
FIGO stage I and II [8] invasive (epithelial or non-epithelial) ovarian malignancy were considered
for analysis.
2.2. Diagnostic Models
Three diagnostic IOTA methods for the assessment of adnexal masses (the original SRs, SRR and
ADNEX) were evaluated in terms of their ability to discriminate between benign disease and stage
I–II primary ovarian malignancy. These methods were developed on data of earlier IOTA phases.
Hence, this is a temporal validation study, including new centers. The original IOTA SRs result in
a classification of ovarian masses as benign, malignant, or inconclusive. In this work, we classified
inconclusive cases as malignant. The SRR yields a predicted probability of ovarian malignancy. The
ADNEX model provides the predicted risks of four different subclasses of malignant adnexal tumors
(borderline, stage I invasive, stage II-IV invasive or metastatic cancer). When using the ADNEX
model, the probability of malignancy is computed as the sum of the predicted probabilities for all
malignant subtypes (including borderline tumors). We validated the version of ADNEX that does not
use serum cancer antigen 125 (CA125) measurements as a predictor, because CA125 results are not
always available in women with benign or stage I–II tumors (results for serum CA125 measurements
were missing for 45% of women in our database). ADNEX with and without CA125 has similar
ability to predict malignancy [25]. Both SRR and ADNEX were initially developed on data from IOTA
phases 1 and 2, validated on data from IOTA 3, and then refitted on all data [24,25]. In this study,
we used the initial versions of SRR and ADNEX that were not refitted using IOTA 3 data. We also
evaluated the performance of subjective assessment.
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2.3. Statistical Methods
All strategies were evaluated in terms of their ability to discriminate between benign and
malignant masses. The area under the receiver-operator characteristic curve (AUC) was computed
for ADNEX and the SRR. We also calculated the sensitivity and specificity for ADNEX and the SRR
at risk thresholds of 1%, 10%, 20%, and 30%, as well the sensitivity and specificity of the original
SRs (classifying inconclusive results as malignant) and subjective assessment. Subgroup analyses
were performed for pre- and postmenopausal women. R software (version 3.3.1.) was used for all
calculations (R: A language and environment for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria, Available online: http/www.r-project.org/). The pROC package and
binom packages were used to calculate Delong [32] and Wilson [33] confidence intervals for AUCs and
sensitivity/specificity, respectively. The Transparent Reporting of a multivariable prediction model for
Individual Prognosis or Diagnosis (TRIPOD) guidelines [34] were used for reporting in this study.
3. Results
In total, 2541 women with adnexal masses were enrolled in IOTA phase 3. We excluded 138 women
from the final data set after the application of exclusion criteria [31].
Of the remaining 2403 patients, 1423 had a benign mass. Patients with borderline tumors,
stage III–IV primary invasive malignancies, and metastatic cancer were excluded from the analysis.
The resulting database for analysis consisted of 1653 women from 18 centers, 230 of which had stage
I–II invasive ovarian malignancy. Patient and tumor characteristics are represented in Table 1. Of the
women included, 34.6% were postmenopausal. Histology findings are listed in Table 2.
Table 1. Descriptive statistics of the sample.
Variable
Result
Benign Tumor Early Stage Malignancy (I and II)
N 1423 (86.1%) 230 (13.9%)
Age (years) 44 (33 to 56) 55 (42 to 66)
Postmenopausal 447 (31.4%) 125 (54.3%)
CA125 (IU/L), if available a 21 (12 to 46) 55 (20 to 207)
Maximum tumor diameter (mm) 64 (47 to 90) 103 (68 to 143)
Presence of solid components 474 (33.3%) 214 (93.0%)
Maximum diameter of the solid component (if any, mm) 28 (13 to 54) 62 (37 to 93)
Locularity
Unilocular 595 (41.8%) 2 (0.9%)
Unilocular-solid 141 (9.9%) 34 (14.8%)
Multilocular 354 (24.9%) 14 (6.1%)
Multilocular-solid 179 (12.6%) 93 (40.4%)
Solid 154 (10.8%) 87 (37.8%)
Number of locules (if any) 1 (1 to 3) 5 (1.5 to 6)
Acoustic shadows 265 (18.6%) 17 (7.4%)
Intratumoral blood flow
No blood flow 574 (40.3%) 5 (2.2%)
Minimal blood flow 563 (39.6%) 54 (23.5%)
Moderate blood flow 239 (16.8%) 95 (41.3%)
Very strong blood flow 47 (3.3%) 76 (33.0%)
Irregular internal cyst wall 385 (27.1%) 151 (65.7%)
Presence of ascites 18 (1.3%) 33 (14.3%)
Presence of papillary structures 180 (12.6%) 54 (23.5%)
Number of papillary structures (if present) 1 (1 to 3) 3 (2 to 4)
a CA125: cancer antigen 125. There were 683 (48%) missing values for CA125 for benign tumors and 64 (28%) for
early stage tumors.
Results are shown as medians (interquartile range) for continuous and ordinal variables, and as
N (%) for categorical variables. Possible values for “Number of locules” are 1 = presence of one locule,
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2 = presence of two locules, 3 = presence of three locules, 4 = presence of four locules, 5 = presence of
five to ten locules, 6 = presence of more than ten locules. Possible values for “Number of papillary
structures” are 1 = presence of one papillary structure, 2 = presence of two papillary structures,
3 = presence of three papillary structures, 4 = presence of more than three papillary structures.
Table 2. Overview of histologic outcomes (N, %).
Histology N (%)
Endometrioma 344 (20.8%)
Teratoma 231 (14.0%)
Simple cyst + parasalpingeal cyst 106 (6.4%)
Functional cyst 40 (2.4%)
Hydrosalpinx + salpingitis 47 (2.8%)
Peritoneal pseudocyst 18 (1.1%)
Abscess 17 (1.0%)
Fibroma 130 (7.9%)
Serous cystadenoma 259 (15.7%)
Mucinous cystadenoma 183 (11.1%)
Rare benign 48 (2.9%)
Primary invasive (epithelial) cancer stage I 128 (7.7%)
Primary invasive (epithelial) cancer stage II 47 (2.8%)
Rare primary invasive malignancy stage I or II * 55 (3.3%)
* Includes germ cell tumors and sex cord-stromal tumors.
Regarding the identification of stage I–II primary ovarian malignancy as malignant disease,
the original SRs (classifying inconclusive cases as malignant) had a sensitivity and specificity
(95% confidence intervals) of 94.3% (90.6% to 96.7%) and 73.4% (71.0% to 75.6%). Subjective assessment
had a sensitivity and specificity of 90.0% (85.4% to 93.2%) and 86.7% (84.9% to 88.4%), respectively.
Considering the discrimination of benign and malignant disease in the study population of patients
with benign masses and stage I–II primary ovarian malignancy the AUCs of the SRR and ADNEX
model were 0.917 (0.902 to 0.933) and 0.920 (0.905 to 0.934), respectively. The sensitivity and specificity
for these risk prediction models differ depending on the selected risk threshold to predict malignancy.
Table 3 summarizes the sensitivity and specificity for the two models at different risk thresholds.
Table 3. Sensitivity and specificity for Assessment of Different NEoplasias in the adneXa (ADNEX)
model and Simple Rules Risk (SRR) model at various risk thresholds (percent (95% confidence interval)).
Risk Threshold Statistic ADNEX SRR
1%
Sensitivity 100.0% 100.0%
(98.4% to 100.0%) (98.4% to 100.0%)
Specificity 19.4% 38.0%
(17.4% to 21.5%) (35.5% to 40.6%)
10%
Sensitivity 97.4% 97.0%
(94.4% to 98.8%) (93.9% to 98.5%)
Specificity 69.5% 65.1%
(67.1% to 71.8%) (62.6% to 67.6%)
20%
Sensitivity 91.3% 94.3%
(87.0% to 94.3%) (90.6% to 96.7%)
Specificity 79.7% 74.3%
(77.5% to 81.7%) (71.9% to 76.5%)
30%
Sensitivity 84.5% 88.3%
(80.5% to 89.6%) (83.5% to 91.8%)
Specificity 84.5% 81.1%
(82.6% to 86.3%) (79.0% to 83.0%)
When stratifying for menopausal status, the original SRs (classifying inconclusive cases as
malignant) had a sensitivity and specificity of 94.3% (88.1% to 97.4%) and 77.3% (74.5% to 79.8%) in
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premenopausal patients, and 94.4% (88.9% to 97.3%) and 64.9% (60.3% to 69.2%) in postmenopausal
patients. Subjective assessment had a sensitivity and specificity of 87.6% (80.0% to 92.6%) and 89.0%
(86.9% to 90.8%) in premenopausal patients, and 92.0% (85.9% to 95.6%) and 81.7% (77.8% to 85.0%) in
postmenopausal patients.
In premenopausal women, the AUCs of the SRR and ADNEX model were 0.932 (0.913 to 0.950)
and 0.932 (0.913 to 0.950), respectively. In postmenopausal women, the AUCs of the SRR and ADNEX
model were 0.882 (0.853 to 0.912) and 0.885 (0.858 to 0.912), respectively.
Table 4 summarizes the sensitivity and specificity for the two models at different risk thresholds
for pre- and postmenopausal women.
Table 4. Sensitivity and specificity by menopausal status for Assessment of Different NEoplasias in
the adneXa (ADNEX) model and Simple Rules Risk (SRR) model at various risk thresholds (percent
(95% confidence interval)).
Risk
Threshold
Statistic
ADNEX SRR
Premenopausal Postmenopausal Premenopausal Postmenopausal
1%
Sens
100.0% 100.0% 100.0% 100%
(96.5% to 100.0%) (97.0% to 100%) (96.5% to 100.0%) (97.0% to 100.0%)
Spec 25.8% 5.4% 41.4% 30.6%
(23.2% to 28.7%) (3.6% to 7.9%) (38.3% to 44.5%) (26.6% to 35.1%)
10%
Sens
94.3% 100% 98.1% 96.0%
(88.1% to 97.4%) (97.0% to 100%) (93.3% to 99.5%) (91.0% to 98.3%)
Spec 77.8% 51.5% 70.6% 53.2%
(75.1% to 80.3%) (46.8% to 56.1%) (67.7% to 73.4%) (48.6% to 57.8%)
20%
Sens
86.7% 95.2% 94.3% 94.4%
(78.9% to 91.9%) (89.9% to 97.8%) (88.1% to 97.4%) (88.9% to 97.3%)
Spec 85.6% 66.9% 78.5% 65.1%
(83.2% to 87.6%) (62.4% to 71.1%) (75.8% to 80.9%) (60.6% to 69.4%)
30%
Sens
78.1% 92.0% 84.8% 91.2%
(69.3% to 84.9%) (85.9% to 95.6%) (76.7% to 90.4%) (84.9% to 95.0%)
Spec 89.5% 73.6% 84.1% 74.5%
(87.5% to 81.3%) (96.3% to 77.5%) (81.7% to 86.3%) (70.3% to 78.3%)
4. Discussion
This validation of IOTA ultrasound-based rules and risk prediction models showed good test
performance to discriminate between benign disease and stage I–II ovarian malignancy before surgery.
The strength of this study is the use of a large international database in which information was
prospectively collected using well-defined terms, definitions, and measurement methods [19]. The large
sample size and the participation of different types of centers are likely to yield generalizable results.
A limitation of our study is that the diagnostic methods were validated exclusively on patients
who underwent surgery. This does not reflect clinical practice, where some masses are managed
expectantly, but it allowed us to use histological diagnosis as the gold standard. We are awaiting the
results of IOTA phase 5, in which IOTA methods are validated on consecutively collected adnexal
masses of all kinds, including those managed conservatively. A second limitation is that all ultrasound
examiners in the study were very experienced. Our results might not necessarily be applicable to less
experienced operators. However, published studies have shown that the IOTA SRs and ADNEX retain
their performance in the hands of less experienced examiners [27,28,35–41]. This is likely to be true
also for the SRR model, because the same ultrasound variables are used in the original SRs are used
to calculate the risks of the SRR model. A third limitation of our study is that not all histopathology
information necessary to classify the tumors into type I and type II epithelial malignancies had been
collected. This is explained by the fact that patient recruitment for IOTA 3 started in 2009, before the
dualistic model of ovarian carcinogenesis [42] was widely accepted.
The findings of our study show that the performance of IOTA methods for differentiating
benign disease from stage I–II primary ovarian malignancy is not much lower than the performance
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for the discrimination of benign from all malignant disease (all malignant subtypes grouped
together) [24,25,31]. In the original publications including all IOTA 3 patients, validation AUCs
(95% confidence intervals) regarding discrimination between benign and malignant disease for SRR
and ADNEX (without CA125) were 0.917 (0.902–0.930) [24] and 0.932 (0.922–0.941) [25], respectively.
Sensitivity and specificity for the original SRs on validation in the same population were 95.3% (93.1%
to 96.9%) and 74.1% (67.7% to 79.7%), respectively [24,25,31].
Borderline malignant tumors were excluded from our analysis. These tumors are known to
be more difficult to classify as benign or malignant [25,43,44]. On the other hand, borderline (i.e.,
non-invasive malignant) ovarian tumors rarely precede invasive epithelial ovarian carcinoma [45,46].
More clinically relevant is the correct identification of early stage primary invasive tumors, where
prompt and adequate surgical staging is important for improving survival [47]. Detection of stage
I-II ovarian cancer is particularly important for screening for ovarian cancer to be successful. The
aim of screening for ovarian cancer is to decrease ovarian cancer mortality. For this to be possible,
screening should result in a shift towards earlier stages at detection, i.e., the detection rate of stage I–II
ovarian cancer should be high. However, a shift towards earlier detection of ovarian cancer has been
shown in only two [9,11] of three randomized controlled trials [9–11] on ovarian cancer screening,
and none of the two completed screening trials has shown conclusive evidence of decreased ovarian
cancer mortality in the screened group [10,11]. In the two completed randomized trials on ovarian
cancer screening [10,11], the ultrasound criteria to define an abnormal screening result were subjective
or arbitrary. As a result, many patients with benign disease were scheduled for surgery, i.e., a large
number of operations were performed to detect one cancer case. We speculate that the positive
predictive value of an abnormal screen result could be improved if the IOTA methods were used
to define an abnormal scan result. To the best of our knowledge, the discriminative or predictive
performance of the IOTA methods has never been assessed in a screening population.
About 90% of invasive malignant ovarian tumors are epithelial [48]. The dualistic model
proposed by Shih and Kurman highlights the heterogeneity of ovarian carcinoma and implies that
ultrasound-based screening will not be effective in detecting all types of ovarian carcinoma. Type I
tumors (low-grade serous, low-grade endometrioid, clear cell, and mucinous) are slow growing, attain
a large size while still confined to the ovary, and are thus likely to be detected early by transvaginal
ultrasound. Unfortunately, these lesions constitute only 25% of ovarian cancers and account for
only approximately 10% of ovarian cancer deaths. On the other hand, type II tumors (high-grade
serous and undifferentiated carcinomas, and malignant mixed mesodermal tumors (carcinosarcomas))
represent 75% of all ovarian carcinomas, are responsible for 90% of ovarian cancer deaths, and may
originate outside the ovary. These tumors are almost never confined to the ovary at diagnosis, making
their diagnosis at an early point in the disease course challenging [42,49]. To allow detection of this
aggressive type of ovarian cancer, there is ongoing search for sensitive biomarkers expressed early in
ovarian carcinogenesis. More recently, there is increasing interest in the use of genomic profiling as
a potential candidate for the detection of ovarian malignancies [50,51]. Further research should explore
whether IOTA methods may serve as a second stage test in a program of ovarian cancer screening to
avoid unnecessary surgery without delaying a diagnosis of ovarian cancer.
5. Conclusions
This analysis shows that the IOTA methods have good ability to discriminate between stage I–II
ovarian malignancy and benign adnexal lesions prior to surgery. The potential use of IOTA methods
as a second stage test in ovarian cancer screening should be the subject of further investigation.
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